Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04967170 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Platelet Rich Plasma to Treat Vulvar Lichen Sclerosus
A Phase 1 study of Vulvar Lichen Sclerosus, sponsored by Jennifer R. Arthurs.
- Active
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04967170 is a Phase 1 study of Vulvar Lichen Sclerosus that is active but no longer recruiting, run by Jennifer R. Arthurs. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04967170, a Phase 1 study of Vulvar Lichen Sclerosus, is active but no longer recruiting, sponsored by Jennifer R. Arthurs.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purposes of this study are to determine the safety and feasibility of autologous platelet-rich plasma for the treatment of vulvar lichen sclerosus, and to determine the efficacy of autologous platelet-rich plasma for the treatment of vulvar lichen sclerosus.
Conditions Studied
Interventions
- OTHER Sham Procedure
- BIOLOGICAL Autologous Platelet-Rich Plasma (PRP)
Study Locations (1)
Florida
- Mayo Clinic in Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-01-19 |
| Est. Completion | 2026-06-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04967170
The ClinicalTrials.gov registry entry for NCT04967170 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jennifer R. Arthurs, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Vulvar Lichen Sclerosus appearing as the primary indexed condition, and to 2 interventions - of which Sham Procedure is the first listed.
NCT04967170 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT04967170 about?
NCT04967170 is a clinical study titled "A Study to Evaluate Platelet Rich Plasma to Treat Vulvar Lichen Sclerosus". The purposes of this study are to determine the safety and feasibility of autologous platelet-rich plasma for the treatment of vulvar lichen sclerosus, and to determine the efficacy of autologous platelet-rich plasma for the treatment of vulvar lichen sclerosus.
What is the current status of trial NCT04967170?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2022-01-19. Estimated completion is 2026-06-02.
What conditions does trial NCT04967170 study?
This clinical trial studies the following conditions: Vulvar Lichen Sclerosus.
What interventions are being tested in trial NCT04967170?
The interventions under investigation include: Sham Procedure (OTHER), Autologous Platelet-Rich Plasma (PRP) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04967170?
This trial is sponsored by Jennifer R. Arthurs, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04967170 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vulvar Lichen Sclerosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.